Ubrogepant

Ubrogepant is a prescription medicine used for the acute treatment of migraine attacks with or without aura in adults.

• Ubrogepant is available under the following different brand names: Ubrelvy

Adult dosage

Tablet

• 50mg
• 100mg

Migraine

Adult dosage

• 50-100 mg orally for acute migraine
• If needed, may take the second dose at least 2 hours after the initial dose
• Maximum dose: 200 mg/24 hours
• Safety of treating more than 8 migraines/30-day period not established
• Limitations of Use
  • Not indicated for migraine prevention

Dosage Considerations – Should be Given as Follows: 

• See “Dosages”

Common side effects of Ubrogepant include:

• nausea, 
• sleepiness, and
• dry mouth.

Serious side effects of Ubrogepant include:

• none

Rare side effects of Ubrogepant include:

• none 

This is not a complete list of side effects and other serious side effects or health problems that may occur as a result of the use of this drug. Call your doctor for medical advice about serious side effects or adverse reactions. You may report side effects or health problems to FDA at 1-800-FDA-1088.

If your medical doctor is using this medicine to treat your pain, your doctor or pharmacist may already be aware of any possible drug interactions and may be monitoring you for them. Do not start, stop, or change the dosage of any medicine before checking with your doctor, health care provider, or pharmacist first.

• Ubrogepant has severe interactions with the following drugs:
  • atazanavir
  • chloramphenicol
  • cobicistat
  • conivaptan
  • idelalisib
  • itraconazole
  • lopinavir
• Ubrogepant has serious interactions with at least 43 other drugs.
• Ubrogepant has moderate interactions with at least 39 other drugs.
• Ubrogepant has minor interactions with no other drugs. 

This information does not contain all possible interactions or adverse effects. Visit the RxList Drug Interaction Checker for any drug interactions. Therefore, before using this product, tell your doctor or pharmacist of all the products you use. Keep a list of all your medications with you and share this information with your doctor and pharmacist. Check with your health care professional or doctor for additional medical advice, or if you have health questions, concerns.

Contraindications

• Coadministration with strong CYP3A4 inhibitors

Effects of drug abuse

• None

Short-Term Effects

• See “What Are Side Effects Associated with Using Ubrogepant?”

Long-Term Effects

• See “What Are Side Effects Associated with Using Ubrogepant?”

Cautions

Drug interaction overview

• BCRP and/or P-gp only inhibitors: Ubrogepant dosage reduction recommended
• CYP3A4 inhibitors
  • Contraindicated with strong CYP3A4 inhibitors
  • Ubrogepant dosage reduction recommended if coadministered with moderate or weak CYP3A4 inhibitors
• CYP3A4 inducers
  • Avoid coadministration with strong CYP3A4 inducers
  • Ubrogepant dosage increase recommended if coadministered with moderate or weak CYP3A4 inducers

Pregnancy and Lactation

• Data are not available regarding the risk associated with use in pregnant women

Clinical considerations

• Published data have suggested that women with migraine may be at increased risk of preeclampsia and gestational hypertension during pregnancy

Lactation

• Data are not available regarding presence in human milk, effect on breastfed infants, or effects on milk production